Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avigbagene parvec - Spur Therapeutics

Next Previous
Drug Profile

Avigbagene parvec - Spur Therapeutics

Alternative Names: FLT-200; FLT-201; FLT200/201

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College London
  • Developer Spur Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gaucher's disease type I

Most Recent Events

  • 08 Oct 2025 Pharmacodynamic data from the phase I/II GALILEO-1 trial in Gaucher’s disease type I released by Spur Therapeutics
  • 07 Oct 2025 Freeline Therapeutics plans a phase III trial in Gaucher's disease type I in first half of 2026
  • 27 May 2025 Adverse events, pharmacokinetics and pharmacodynamics data from a preclinical trial in Gaucher's disease released by Spur Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top